Guggenheim Reaffirms “Buy” Rating for Endo International PLC (ENDP)
Endo International PLC (NASDAQ:ENDP)‘s stock had its “buy” rating reaffirmed by equities researchers at Guggenheim in a research report issued to clients and investors on Saturday. They presently have a $35.00 price objective on the stock. Guggenheim’s target price would indicate a potential upside of 76.23% from the stock’s current price.
ENDP has been the topic of a number of other research reports. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $40.00 price objective on shares of Endo International PLC in a research note on Tuesday, July 26th. Leerink Swann reissued a “market perform” rating and issued a $22.00 price objective on shares of Endo International PLC in a research note on Friday, September 23rd. Piper Jaffray Cos. set a $19.00 price objective on Endo International PLC and gave the stock a “hold” rating in a research note on Tuesday, August 9th. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Endo International PLC in a research note on Wednesday, June 29th. Finally, Vetr raised Endo International PLC from a “hold” rating to a “buy” rating and set a $21.95 price objective on the stock in a research note on Thursday, August 25th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $37.50.
Shares of Endo International PLC (NASDAQ:ENDP) traded up 0.25% during mid-day trading on Friday, reaching $19.86. The company’s stock had a trading volume of 5,277,128 shares. The company’s market capitalization is $4.42 billion. The firm’s 50 day moving average is $20.70 and its 200-day moving average is $20.48. Endo International PLC has a 52-week low of $12.56 and a 52-week high of $69.17.
Endo International PLC (NASDAQ:ENDP) last posted its quarterly earnings data on Monday, August 8th. The company reported $0.86 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.12. Endo International PLC had a positive return on equity of 15.54% and a negative net margin of 25.90%. The company had revenue of $921 million for the quarter, compared to the consensus estimate of $873.50 million. During the same quarter in the previous year, the business earned $1.08 EPS. The company’s quarterly revenue was up 25.3% compared to the same quarter last year. Analysts forecast that Endo International PLC will post $4.56 EPS for the current year.
Institutional investors have recently bought and sold shares of the company. Aperio Group LLC boosted its position in Endo International PLC by 1.7% in the first quarter. Aperio Group LLC now owns 43,200 shares of the company’s stock valued at $1,216,000 after buying an additional 732 shares during the period. Canada Pension Plan Investment Board boosted its position in Endo International PLC by 33.0% in the first quarter. Canada Pension Plan Investment Board now owns 9,019 shares of the company’s stock valued at $254,000 after buying an additional 2,237 shares during the period. State Street Corp boosted its position in Endo International PLC by 1.0% in the first quarter. State Street Corp now owns 8,625,765 shares of the company’s stock valued at $242,813,000 after buying an additional 81,814 shares during the period. Meeder Asset Management Inc. purchased a new position in Endo International PLC during the first quarter valued at approximately $139,000. Finally, Riverhead Capital Management LLC boosted its position in Endo International PLC by 5.5% in the first quarter. Riverhead Capital Management LLC now owns 32,435 shares of the company’s stock valued at $913,000 after buying an additional 1,694 shares during the period. 96.64% of the stock is owned by institutional investors and hedge funds.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.